Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P15088 (mast cell)
 14,925 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The in vitro production of histamine releasing factor (HRF) by lymphoid cells of rats, both normal and infected with Nippostrongylus brasiliensis, has been studied. Spleen cells and thymocytes were cultured either alone or in the presence of mitogen (PHA, 10 and 50 micrograms/ml) and the dialysed cell-free supernatants were tested for histamine releasing activity on rat peritoneal and pleural mast cell in vitro. We found that spleen cells and thymocytes of normal rats stimulated with PHA in 24 h cultures generated a factor which released histamine and 5-hydroxytryptamine from mast cells, and this ability was potentiated following N. brasiliensis infection of rats - lymphoid cells donors. Pleural mast cells were more sensitive to the action of HRF than peritoneal cells. Rat HRF had an apparent m.w. of 50,000 to 70,000 daltons as determined by gel chromatography and was a heat stable protein inducing histamine release from homologous mast cells in a very rapid (complete in 1-2 min at 37 degrees C), dose and temperature dependent secretory process.
 ...
PMID:Rat lymphoid cell--derived histamine and 5-hydroxytryptamine releasing factor. 128 Apr 98

The histamine release induced by compound 48/80, bradykinin or polyethylenimine with a molecular weight of 600 (PEI6) was inhibited by wheat germ agglutinin (WGA) and phytohemagglutinin E-subunits (PHA-E4), and the inhibition was specifically reversed by N-acetyl glucosamine and N-acetyl galactosamine, respectively. Concanavalin A (Con A) and phytohemagglutinin L-subunits (PHA-L4) did not inhibit the histamine release induced by compound 48/80, bradykinin or PEI6. The histamine release induced by substance P was also inhibited sugar-specifically by WGA and PHA-E4. The binding sites for compound 48/80, bradykinin, PEI6 and substance P, therefore, seemed to especially overlap each other. These binding sites were found to be glycoproteins having affinities to WGA and PHA-E4, but not to Con A and PHA-L4. The binding of WGA and PHA-E4 to the glycoproteins resulted in inhibition of the interaction between the basic secretagogues including bradykinin and substance P and their binding sites on the mast cells. The bindings of five lectins to mast cell glycoproteins were examined by lectin-blotting. Several glycoproteins, which had specific affinities to WGA and PHA-E4, but not to Con A and PHA-L4 were detected. We assumed that the binding sites for basic secretagogues which are coupled with histamine-releasing mechanisms exist among these glycoproteins. A 41-kDa protein (alpha-subunit of pertussis toxin-sensitive G protein) was not detected by WGA, suggesting that the binding sites for the basic secretagogues were not G proteins.
 ...
PMID:Sugar-specific inhibitory effects of wheat germ agglutinin and phytohemagglutinin-E4 on histamine release induced by basic secretagogues from rat peritoneal mast cells and their possible action sites. 172 87

Calcitonin gene-related peptide (CGRP) is known to block Con A and PHA induced T cell proliferation. As a first step in determining the role of this peptide in T cell education and function we have studied the distribution of CGRP within the developing mouse thymus using immunocytochemistry. CGRP-like immunoreactivity (CGRP-IR) was found in the thymic nerves in close proximity to blood vessels in the 17-day-old embryonic mouse thymus. A discrete population of small cells at the cortico-medullary junction also stained intensely for CGRP. As the mouse thymus reached maturity (three to eight weeks) CGRP innervation became more dense, with fibers running along the vasculature at the cortico-medullary boundary, then branching into the cortical and medullary regions. Some fibers were invested in the blood vessels while a large portion formed varicosities among the cells of the thymus. In the mature thymus, the small CGRP-IR cortico-medullary cells were more numerous, and CGRP-IR was also found in subcapsular and trabecular mast cells. The pattern of innervation remained the same in the aging mouse thymus (six months), but there appeared to be somewhat fewer cortico-medullary cells and an increase in mast cell number. In the aged (eighteen months) thymus, the small CGRP-IR cortico-medullary cells were rarely seen, but mast cells were more numerous, most of which stained positively for CGRP, in the connective tissue. Nerves containing CGRP-IR generally had the same distribution as in the younger mice but appeared somewhat truncated. The distribution of CGRP-IR nerves in the mouse thymus at different stages of development was similar to that reported for cholinergic (AChE-positive) nerves. Since the brain-stem vagal nuclei have been shown by retrograde transport studies to project to the thymus as well as to contain CGRP-IR neurons, our findings suggest that CGRP-IR thymic nerves may be derived from the vagus complex.
 ...
PMID:Calcitonin gene-related peptide in the developing and aging thymus. An immunocytochemical study. 185 88

Mononuclear cells from human umbilical cord blood were separately cultured either in the presence of phorbol ester-phytohemagglutin-leukocyte-conditioned medium (PE-PHA-LCM) or PHA-LCM. Cells cultured in PE-PHA-LCM released histamine following calcium ionophore and compound 48/80 challenge. However, there was a similar histamine release from cells cultured in the presence of PHA-LCM following calcium ionophore but not following compound 48/80 challenge. Neutrophil chemotactic activity (NCA), recognized to be one of the markers for mast cell activation, was detected following calcium ionophore and anti-IgE challenge from the supernatant of cells cultured in the presence of PHA-LCM, suggesting unique features in the cells studied.
 ...
PMID:Mediator release from basophilic cells derived from cultured cord blood cells. 243 47

It has been suggested that reserpine blocks expression of delayed hypersensitivity (DH) reactions by depleting tissue mast cells of serotonin, thereby preventing a T cell-dependent release of mast cell serotonin necessary to localize and to amplify the DH response. However, reserpine blocks expression of DH in mast cell-deficient mice. Recently, we showed that the ability of reserpine to interfere with the expression of contact sensitivity was independent of an effect on mast cells, but reflected an effort of the drug on effector T cell function. In the present study we evaluated the mechanisms by which reserpine abrogates the expression of T cell functions. By using human peripheral blood mononuclear cells or enriched T cell populations we found that the drug inhibited, in a dose-dependent fashion, the proliferation of T cells after mitogen stimulation. Reserpine also interfered with the mitogen-induced IL-2 production by these cells, but the IL-2 receptor expression, as measured by immunofluorescence, was unaffected. Despite this, in the continuous presence of reserpine, exogenous IL-2 did not bypass reserpine inhibition of PHA-induced proliferation. By using the fluorescent indicator quin-2 we have demonstrated that preincubation with reserpine prevented the increase of cytosolic free calcium, which accompanies PHA-induced proliferative responses of human T lymphocytes. These results identify the sites of action of reserpine in human T lymphocytes and are sufficient to explain its ability to block cell-mediated immune responses in vitro and in vivo.
 ...
PMID:Characterization of the interference of T cell activation by reserpine. 251 Sep 39

Activation of lymph nodes by the T-cell mitogens PHA and Con A is correlated with a depletion of lymphatic mast cells. This result, and our earlier reports on the depletion of mast cells in lymph nodes stimulated by allogeneic and tumour cells, as well as on the elevation of mast cell number in thymus-less 'nude' mice, lead us to the conclusion that antigen- or mitogen-stimulated T lymphocytes produce lymphokine(s) which degranulates mast cells and/or is responsible for their negative chemotaxis.
 ...
PMID:Lymphatic mast cells in response to in vitro stimulation by non-specific T-cell mitogens. 387 50

The effect of repeated infestations of Ixodes ricinus (L.) nymphs on BALB/c mice was studied. Four successive infectations resulted in an increase of tick feeding success. Tick yield and mean engorged weight increased and the length of the feeding period was reduced significantly (P < 0.05-0.01). The increase of specific anti-tick antibodies was not significant (P > 0.05). The blastogenic response of spleen lymphocytes to T-cell mitogens (Con A and PHA-P) was unimpaired or slightly enhanced, whereas the response to B-cell activators (LPS and PWM) was suppressed, as was the total antibody generation in vitro. The numbers of mast cells in murine skin at the tick attachment sites slightly decreased during the third infestation. The suppression of B-cell competence and of antibody generation, together with decrease of skin mast cell numbers in tick attachment sits, are considered to be responsible for enhancement of tick feeding success.
 ...
PMID:Immunosuppression and feeding success of Ixodes ricinus nymphs on BALB/c mice. 778 20

Histamine-releasing factor (HRF) consists of a group of cytokines that can cause basophil/mast cell to release histamine, however, the composition of HRF still remains undefined. This study was designed to measure the concentrations of chemokines in asthmatic children receiving immunotherapy. Peripheral blood mononuclear cells culture supernatants were obtained from six asthmatic children before and four, eight months after immunotherapy (IT). The levels of monocyte chemotactic and activating factor (MCAF), macrophage inflammatory protein-1a (MIP-1a), regulated on activation normal T-cell expressed and secreted (RANTES) and interleukin-8 (IL-8) spontaneously and after stimulation with PHA and mite allergen in the supernatants. The data showed: 1) The levels of MCAF and MIP-1a increased four months, and decreased eight months, after IT; 2) By contrast, the level of RANTE increased after IT; 3) The level of IL-8 also tended to increase after IT. Abnormal chemokine production may contribute to the pathogenesis of bronchial asthma and restoration of normal chemokine production may be used to partially explain the clinical efficacy of immunotherapy.
 ...
PMID:Change of chemokines during immunotherapy in asthmatic children. 894 25

This manuscript updates an analysis of the foremost clinical investigation of PHA for aplastic anemias and other disorders associated with impaired hematopoiesis during the years 1963-1967. Humble displayed remarkable insight in motivating the trials long before the recent era during which these disorders have become much better understood. That investigation actually consisted of a series of small pilot studies totaling only 44 patients involving all categories in the aplastic group and 15 miscellaneous disorders mostly neoplastic or premalignant. The most serious of several faults with the studies was the inadequacy of dosages applied, yet much better results were observed than might have been anticipated. Mitogens such as the L4 isolectin of PHA might be applied to treat aplastic anemias in three different ways. (1) For milder direct cytotoxicity types, a stimulating regimen should be applied to increase the production of growth factors and thereby hasten recovery from aplasia. (2) Where hematopoietic stem cell allo-engraftment is needed to replace severely damaged marrow, the mitogen should be included in the preparative regimen. (3) The suppressive protocol of a mitogen that maintains total T cell activation should be added to an established drug regimen such as cyclosporin and antilymphocyte globulin in treating the immuno-mediated aplastic anemias not only to provide superior suppression but to help prevent the late emergence of clonal disorders. The models of L4 isolectin application present advantages not fully offered by any of the other immuno-therapies currently available: broad scope of activities, low morbidity, ease of administration, favorable cost-effectiveness, assurance of reconstituted immune competence, and high potential for cure. However, a more potent mitogen than PHA-L4 not inhibited by serum glycoproteins or immunoglobulins and exhibiting a broader range of modulation would be preferred. A publication by Mann et al. in 1991 suggested that pokeweed mitogen (PWM) showing hundreds of times the potency of PHA-L4 would meet these criteria. Abbreviated reports on two of the studies in the report indicated that PWM had induced lasting remissions of cancers in dogs with nine injections in the mid-range of microgram doses over three weeks. The key study done by Mann himself demonstrated complete disappearance of canine gliomas in a carefully devised humane model applied to five dogs in which the transplantable tumor was established by extradural injection. Also impressive were lasting remissions of autonomous solid neoplasms in four dogs under the care of local veterinarians given PWM supplied by Mann. The critical aspect of these studies, both of which have been extended substantially, is the need keep the dosage within a precisely determined range to avoid loss of efficacy and possibly the occurrence of adverse effects. A review of basic studies now indicates the principle mechanism of response to be binding of PWM with tumor cells that then attract mast cells generated by stem cell factor the production of which is stimulated by the mitogen. Degranulation of mast cell granules releases TNF-alpha and IL-1 at the tumor site with resulting disappearance of neoplastic tissue in the absence of severe systemic effects. For cancer therapy, this represents a highly effective deviation from the stimulation of multiple pathways of immune response usually surmised with mitogens such as PHA-L4. This interpretation illustrates the probability that alternative plant mitogens, each with its unique properties, will likely become available to complement PHA-L4 or displace it from the prime standing as an immunomodulator.
 ...
PMID:PHA for aplastic anemias: the alpha but not the omega of mitogen therapies. 1085 Mar 47

In the present study we show the capacity of an extract of the fern Polypodium leucotomos (PLE) to partially inhibit the production of cytokines showing a Th1 pattern (IL-2, IFN-gamma and TNF-alpha) in human PHA-stimulated peripheral blood mononuclear cells. The percentage of inhibition was 24% for IL-2, 72% for INF-gamma and 53% for TNF-alpha. With regard to Th2 cytokines, the addition of PLE resulted in a significant increase (33%) in IL-10 production. Surprisingly, the production of the inflammatory cytokine IL-6 was completely abolished (100% inhibition) by PLE at all doses tested. In a second experiment in vivo we show that, the topical application of PLE to the skin of hairless albino mice (Skh-1) significantly diminished the mast cell infiltrate as well as the number of blood vessels triggered by chronic ultraviolet B (UVB) irradiation. These data show that PLE moderately inhibits the immunological Th1 responses, thus explaining the immunosuppressive as well as the anti-inflammatory and antioxidant activities reported in other studies carried out with PLE. The clear inhibitory effect on TFN-alpha and IL-6 production strongly suggest that this may be the mechanism by which PLE: (a) inhibits angiogenesis in vivo in the mouse model described here, and (b) prevents Langerhans' cells depletion caused by solar irradiation in humans. Taken together, these data suggest that PLE works through the induction of suppressive/anti-inflammatory cytokines such as IL-10 and/or TGF-beta which in turn appear to allow the partial deactivation of macrophages or other accessory cells. These features suggest that PLE could be useful in the treatment of autoaggressive/inflammatory conditions due to an exacerbation of Th1 responses.
 ...
PMID:An extract of the fern Polypodium leucotomos (Difur) modulates Th1/Th2 cytokines balance in vitro and appears to exhibit anti-angiogenic activities in vivo: pathogenic relationships and therapeutic implications. 1092 72


1 2 Next >>